Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development

Contributed by: PR Newswire

Tags

Simcere

More Like This

PR Newswire associated0

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

PR Newswire associated0

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China's First SSTR4 Agonist Targeting Pain

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager